Neutralizing high affinity human monoclonal antibodies specific to RSV F-protein and methods for their manufacture and therapeutic use thereof
US5840298A · kind A · utility
49Cited by
36References
11Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Apr 18, 1996 |
| Grant date | Nov 24, 1998 |
| Priority date | — |
| Expiry date | Apr 18, 2016 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N2799/028
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
A method of treating or preventing RSV infection by the administration of high affinity human monoclonal antibodies having a Kd of about 2.times.10.sup.-9 to 10.sup.-10 molar is provided.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.